Gao JJ, Cheng J, Prowell TM, Bloomquist E, et al. Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis. Lancet Oncol 2021 Oct 14. pii: S1470-2045(21)00472.
PMID: 34656225